Who Paid My Doc
John Gallagher
Endocrinology, Diabetes & Metabolism Omaha, NE Medical Doctor
NPI 1184733966 CMS profile 144988
601 N 30Th St Ste 6712, Omaha, NE 68131
General payments
$14,743
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, John Gallagher of Omaha, NE is reported in the CMS Open Payments database as having received $14,743 across 4 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 82nd percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $23 | 1 | |
| 2020 | General | $11,340 | 2 | |
| 2019 | General | $3,380 | 1 |
Beside peers
- John Gallagher
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to John Gallagher were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | John Gallagher | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $3,380 | $494 | $123–$2,253 | $163 |
| 2020 | $11,340 | $335 | $85–$1,841 | $114 |
| 2021 | $0 | $398 | $88–$1,981 | $132 |
| 2022 | $23 | $364 | $88–$1,568 | $149 |
| 2023 | $0 | $420 | $113–$1,614 | $160 |
| 2024 | $0 | $440 | $121–$1,646 | $164 |
| 2025 | $0 | $507 | $135–$1,838 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 6 billing codesPaid by Medicare
$3,251
Medicare patients
18
Services billed
52
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 67% | |
| Chronic kidney disease | 67% | |
| Arthritis | 67% | |
| Heart failure | 61% | |
| Ischemic heart disease | 61% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
4 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Endocrinology, Diabetes & Metabolism in Nebraska
Marium Ilahi
Endocrinology, Diabetes & Metabolism · Omaha, NE
Cyrus Desouza
Endocrinology, Diabetes & Metabolism · Omaha, NE
Shannon Wakeley
Endocrinology, Diabetes & Metabolism · Lincoln, NE
Timothy Wahl
Endocrinology, Diabetes & Metabolism · Omaha, NE
Leslie Eiland
Endocrinology, Diabetes & Metabolism · Omaha, NE
Anupam Kotwal
Endocrinology, Diabetes & Metabolism · Omaha, NE
Related records
Endocrinology, Diabetes & Metabolism in Nebraska
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in Nebraska
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.